Insights from Digital Pharma Leaders
Refine search
Pharmaceutical
Artificial intelligence is already well established in drug discovery, but the next big test for pharmaceuticals may be less glamorous: making more medicines, more reliably, from existing factories. 15 June 2026
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a regulatory sandbox to examine how artificial intelligence (AI) could support medicines development and drug safety assessment. 9 June 2026
Biotechnology
French pharma major Sanofi has expanded its collaboration with French-American AI biotech Owkin through a multi-year agreement to develop artificial intelligence agents for drug research and development. 8 June 2026
Biotechnology
US pharma giant Pfizer has signed a license agreement with San Francisco-based Chai Discovery, giving its scientists access to the AI company’s drug discovery platform for biologics research. 5 June 2026
Pharmaceutical
US biopharma Alnylam Pharmaceuticals has signed a strategic AI collaboration with Inceptive Nucleics, as it looks to speed up the discovery of RNA interference therapies and broaden its pipeline under its Alnylam 2030 strategy. 4 June 2026
Biotechnology
Danish CNS specialist Lundbeck (and Cradle, a Dutch AI platform for protein engineering, today announced a partnership to help Lundbeck discover and optimize biotherapeutics that ultimately can improve patient outcomes. 3 June 2026
Pharmaceutical
German techbio company Lucera has launched with ambitions to improve decision-making across pharmaceutical research and development using artificial intelligence and a curated biomedical knowledge base. 2 June 2026
Biotechnology
British techbio Genomics has launched Mystra AI, a human genetics-based artificial intelligence platform designed to help drugmakers identify and validate better targets for drug discovery. 2 June 2026
Biotechnology
Genesis Molecular AI and Incyte announced a new kind of deal, with Incyte’s proprietary experimental data powering large-scale training of Genesis’ drug discovery platform. It is backed with $120 million upfront and approximately $5 billion for up to 20 potential targets. 21 May 2026
Pharmaceutical
US pharma major Bristol Myers Squibb has signed a broad artificial intelligence partnership with Anthropic, deploying the tech company’s Claude platform across research, clinical development, manufacturing, commercial operations and corporate functions. 21 May 2026
Pharmaceutical
Incyte and Edison Scientific have announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for the US biopharma’s discovery and development work. 20 May 2026
Pharmaceutical
Chicago, USA-based artificial intelligence company Tempus AI announced a new initiative with US pharma major Bristol Myers Squibb. 15 May 2026
Pharmaceutical
US AI leader Anthropic is expanding further into healthcare and drug development through a new four-year partnership with the Gates Foundation focused on vaccines, disease modeling and health-system operations in lower-income countries. 15 May 2026
Biotechnology
UK-based Isomorphic Labs, the AI-driven drug discovery company spun out of Google DeepMind, has raised $2.1 billion in a Series B financing round. 13 May 2026
Biotechnology
Privately-held Boston, USA, firm Cellular Intelligence has acquired global rights to Novo Nordisk's cell therapy program for Parkinson's disease. 12 May 2026
Pharmaceutical
British pharma major AstraZeneca is expanding its oncology-focused artificial intelligence collaboration with US biotech Immunai in a deal that could bring the smaller company up to $37.5 million over 2026-2027. 8 May 2026
Pharmaceutical
Ahead of a London event on May 12 on how AI is rapidly reshaping how healthcare information is discovered, interpreted and shared, this week's Expert View comes from panellist Sophie Randall, Director of the Patient Information Forum, the UK membership organization for people working in health information and support. 6 May 2026
Biotechnology
Profluent, the frontier AI company pioneering large-scale foundation models for protein design, today announced a multi-program strategic research collaboration with Eli Lilly to develop and commercialize custom site-specific recombinases to address diseases with severe unmet needs. 28 April 2026
Biotechnology
Belgian drugmaker UCB and the University of Southampton have announced a joint three-year project that they have dubbed the Digital Antibody Research Collaboration (DARC). 27 April 2026
Pharmaceutical
Merck & Co and Google Cloud have announced a landmark partnership to enhance the US pharma giant’s digital backbone as an AI-enabled enterprise. 23 April 2026
Pharmaceutical
An Expert View from Ramji Vasudevan, head of life sciences, Altimetrik. 19 September 2025
Pharmaceutical
Lila Sciences has secured $235 million in series A financing, co-led by Braidwell and Collective Global, at a valuation of about $1.23 billion. The Massachusetts-based company, founded by Flagship Pioneering in 2023, is building an artificial intelligence platform designed to automate and accelerate the scientific method across multiple disciplines. 16 September 2025
Pharmaceutical
An Analysis piece finds explainable AI is the new brain behind pharma's decision-making process for PR and insights leaders. 9 September 2025
Biotechnology
Arena BioWorks has named Harvey Berger as its new chief executive officer, according to an announcement on Monday. Mr Berger, a seasoned biotech leader, steps in as the company seeks to advance its preclinical portfolio of small molecules, proteins and monoclonal antibodies from discovery through clinical validation. 9 September 2025
Pharmaceutical
The global digital health market is expanding at breakneck speed, moving from $162 billion in 2024 to nearly $200 billion in 2025, according to research from MarketsandMarkets. By 2030, analysts expect the sector to top $573 billion, driven by demand for personalized, tech-enabled care and rapid adoption of AI, wearables, and remote monitoring tools. 8 September 2025
Pharmaceutical
Cancer research is being transformed by smarter trial design. Tumor-agnostic approvals, adaptive platforms, and biomarker-led enrollment are redefining how drugs are tested and brought to patients. Together, these shifts point to a faster, more precise, and more inclusive era of oncology R&D. 5 September 2025
Pharmaceutical
The Danish government and Danske Regioner have rolled out a national strategy for personalized medicine, drawing praise from industry group Lif. The plan is designed to broaden patient access, strengthen public-private partnerships and accelerate the use of advanced therapies, which Lif described as potentially life-changing for many patients. 1 September 2025
Pharmaceutical
Artificial intelligence has edged past the pilot phase in clinical development. Once a niche add-on, AI is now helping biopharma companies design, recruit, and run trials faster, cheaper, and—crucially—more inclusively. And regulators are starting to pay serious attention. 31 August 2025
Pharmaceutical
Elix has announced that fellow Japanese firm Kyorin Pharmaceutical has adopted Elix Discovery, its proprietary AI-powered drug discovery platform. 27 August 2025
Biotechnology
VantAI, a specialist in generative AI for proximity drug discovery, and Halda Therapeutics, a company focused on regulated induced proximity targeting chimeras (RIPTAC), have agreed a strategic research collaboration worth more than $1 billion in total potential value, inclusive of upfront and milestone payments across multiple targets. 27 August 2025
Biotechnology
US robotics technology company Multiply Labs claims to have developed a new robotic biomanufacturing cluster that achieves a 74% cost reduction for life-saving cell therapies. 22 August 2025
Pharmaceutical
Artificial intelligence is showing promise in improving the detection and management of idiopathic pulmonary fibrosis (IPF), a progressive lung disease that can lead to respiratory failure and severely limit quality of life, according to data and analytics group GlobalData. 13 August 2025
Pharmaceutical
An Expert View from Lindsay Mateo, chief commercial officer at Weave Bio. 12 August 2025
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim and New York-based Click Therapeutics today announced that the pivotal Phase III CONVOKE study of CT-155 (BI 3972080), an investigational prescription digital therapeutic (PDT), met its primary endpoint. 8 August 2025
Pharmaceutical
USA-based biotech DoveTree Medicines has signed a far-reaching partnership with Chinese drug discovery company XtalPi, in a deal worth up to $5.99 billion. 7 August 2025
Biotechnology
US artificial intelligence drug discovery firm Chai Discovery has secured $70 million in Series A funding, drawing backing from several high-profile investors as it seeks to transform how new biologic drugs are engineered. 7 August 2025
Pharmaceutical
Denmark’s pharmaceutical industry body has warned that a new European health data regulation could hamper medical innovation and weaken public-private research efforts if left unchanged. 4 August 2025
Pharmaceutical
The European Medicines Agency has called for updated rules and processes to reflect growing use of artificial intelligence in medicines regulation, following the release of the first annual report from its AI Observatory. 18 July 2025
Biotechnology
US companies SandboxAQ and iOncologi have announced a strategic collaboration to jointly develop, validate, and commercialize a novel high-fidelity mRNA vaccine for glioblastoma, the most common and aggressive malignant brain tumor in adults. 17 July 2025
Pharmaceutical
US pharma firm Lisata Therapeutics has teamed up with tech-bio company GATC Health in a strategic alliance aimed at using artificial intelligence to streamline drug development and improve success rates. 18 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze